Studies in many types of cancer show that B7-H3 might have a negative prognostic role.25–27 Expression of B7-H3 in prostate cancer was associated with poor survival and expression of B7-H3 in stage I to III breast cancer was associated with lymph node metastasis, which is a poor prognostic factor.25,26 While these studies did not evaluate B7-H3 expression by stromal TILs, expression of B7-H3 by stromal TILs may have negative prognostic role by modulating T-cell activity. The gene discussed is CD276; the disease is prostate carcinoma.